Search

Search Constraints

You searched for: Author/Creator Irizarry, Michael C.

Search Results

11. O4‐08‐06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‐18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY, IN ALZHEIMER'S DISEASE (AD). (1st July 2016)

12. P1‐044: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3202626, a Novel Bace1 Inhibitor, in Healthy Subjects and Patients with Alzheimer's Disease. (1st July 2016)

13. P1‐048: PLASMA NF‐L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE‐AD STUDY. (1st July 2019)

14. P1‐326: THE USE OF THE DIGITAL CLOCK DRAWING TEST (DCTCLOCK™) IN THE SCREENING PHASE OF CLINICAL TRIALS FOR ALZHEIMER'S DISEASE. (1st July 2006)

15. P4‐388: TRAILBLAZER‐ALZ (NCT03367403): A PHASE 2 DISEASE‐MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY. (1st July 2006)

16. P4‐401: Combination Therapy with a Plaque‐Specific Abeta Antibody And A Bace Inhibitor Results in Dramatic Plaque Reduction in a Dose‐Dependent Manner in Aged Pdapp Transgenic Mice. (1st July 2016)

18. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease. Issue 4 (15th August 2022)

19. The design of Dominantly Inherited Alzheimer Disease Trial of the anti‐tau antibody, E‐2814, on the DIAN‐TU Tau Next Generation Platform. (31st December 2021)

20. Topographic staging of tau positron emission tomography images. Issue 1 (15th February 2018)